Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaginal cancer.

Perry W Grigsby1

  • 1Department of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University Medical Center, 4939 Children's Place, Suite 5500, Box 8224, St. Louis, MO 63110, USA. grigsbyp@netscape.net

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric thyroid cancer lung metastases and RAI: long-term results.

Journal of pediatric endocrinology & metabolism : JPEM·2026
Same author

Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2024
Same author

SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production.

The Journal of clinical investigation·2023
Same author

SCCA1/SERPINB3 promotes suppressive immune environment via STAT-dependent chemokine production, blunting the therapy-induced T cell responses.

bioRxiv : the preprint server for biology·2023
Same author

Overall survival in patients with FIGO stage IVA cervical cancer.

Gynecologic oncology·2022
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Vaginal carcinoma, a rare gynecologic cancer, is typically treated with radiation therapy. For advanced stages, concurrent cisplatin-based chemotherapy with irradiation is recommended, mirroring cervical cancer treatment protocols.

Area of Science:

  • Gynecologic Oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Vaginal carcinoma is an uncommon gynecologic malignancy.
  • Surgery is an option for carcinoma in situ and very early invasive disease.
  • Radiation therapy is the standard treatment for most vaginal cancers, including early and advanced stages.

Purpose of the Study:

  • To evaluate the efficacy of concurrent chemotherapy and radiation for advanced vaginal carcinoma.
  • To propose a treatment paradigm for advanced vaginal carcinoma based on cervical cancer protocols.

Main Methods:

  • Review of current treatment standards for vaginal and cervical cancers.
  • Analysis of the rationale for extending cervical cancer treatment protocols to vaginal cancer.

Related Experiment Videos

Main Results:

  • No randomized trials comparing radiation alone versus chemoradiation for advanced vaginal carcinoma exist.
  • Concurrent cisplatin-based chemotherapy with irradiation is the standard for advanced cervical carcinoma.
  • Vaginal and cervical carcinomas share similar etiology and epidemiology.

Conclusions:

  • Concurrent cisplatin-based chemotherapy with irradiation should be considered the standard of care for advanced vaginal carcinoma.
  • This approach aims to improve outcomes while preserving anatomy and function, and treating lymph node metastasis.